Core Viewpoint - QianYuan Pharmaceutical expressed intentions to consider expanding into overseas markets if suitable opportunities arise in the future [2] Company Summary - On September 25, QianYuan Pharmaceutical responded to investor inquiries on an interactive platform regarding potential overseas market expansion [2]

证券日报网讯仟源医药9月25日在互动平台回答投资者提问时表示，公司从旧厂区整体搬迁至新厂区， 并增加了精麻药品（口服固体制剂和口服溶液剂）的生产线。 （文章来源：证券日报） ...

Core Insights - The company, Qianyuan Pharmaceutical, reported a steady increase in sales of its smoking cessation drug, Varenicline Tartrate Tablets, since launching its online business in 2024 [2] - The online market share of the drug increased from 8% in the first half of 2024 to 24% in the first half of 2025, indicating significant growth [2] Company Performance - Qianyuan Pharmaceutical's online sales of Varenicline Tartrate Tablets have shown consistent month-over-month growth since the start of its online operations [2] - The increase in market share reflects the company's successful strategy in expanding its online presence and capturing a larger segment of the market [2]

格隆汇9月25日丨仟源医药(300254.SZ)在互动平台表示，公司不涉及脑机接口的相关业务。 ...

Core Viewpoint - QianYuan Pharmaceutical (300254.SZ) has stated that the company does not have any drugs or research and development technologies available for medical beauty or cosmetics [1] Company Summary - QianYuan Pharmaceutical clarified its position regarding the absence of products related to medical beauty and cosmetics [1]

Company Overview - QianYuan Pharmaceutical (SZ 300254) announced on September 22 that its fifth board meeting was held via telecommunication to review the proposal for bank credit borrowing [1] - As of the report date, QianYuan Pharmaceutical has a market capitalization of 2.6 billion yuan [1] Revenue Composition - For the year 2024, the revenue composition of QianYuan Pharmaceutical is as follows: - Pharmaceutical manufacturing accounts for 96.68% - DNA gene preservation and prenatal environment testing services account for 1.93% - Health food accounts for 0.79% - Other businesses account for 0.51% - Commercial activities account for 0.1% [1]

证券代码：300254 证券简称：仟源医药 公告编号：2025-065 山西仟源医药集团股份有限公司 第五届董事会第三十四次会议决议公告 根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》、《公司章程》等的相关规定， 本议案无须提交公司股东会审议。公司董事会授权管理层办理本次授信借款的具 体事宜并签署相关协议。 三、董事会意见 经审议，与会董事认为：公司向山西银行股份有限公司大同分行申请授信借 款不超过人民币 12,000 万元，有利于满足公司经营发展的需要，促进公司业务 的持续稳定发展。同时全资子公司保灵集团、仟源保灵以及公司董事长黄乐群提 供连带责任保证担保符合《深圳证券交易所创业板股票上市规则》、《上市公司自 律监管指引第 2 号——创业板上市公司规范运作》以及《公司章程》等相关法律、 法规和规范性文件的规定，不存在损害公司和股东利益的情况。 表决结果：同意 9 票；反对 0 票；弃权 0 票 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山西仟源医药集团股份有 ...

Core Viewpoint - Shanxi Qianyuan Pharmaceutical Group Co., Ltd. is actively engaging with institutional investors regarding its smoking cessation product, Varenicline Tartrate Tablets, highlighting its multi-channel sales strategy and market expansion efforts [1] Group 1: Product and Sales Strategy - The product utilizes a dual-brand strategy (Parique and Family Pharmacist) and a multi-channel sales model, covering over 100,000 chain stores and more than 600 hospitals, with online sales focused on platforms like JD, Alibaba, and Meituan [1] - Currently, the largest sales volume comes from offline chain channels, while hospital sales have not yet met company expectations [1] Group 2: Market Expansion and Effectiveness - The time to see results from entering new cities or regions depends on the execution and operational capabilities of the pharmacies, with effective pharmacies showing results in 2 to 3 months, while less capable ones may take longer [1] - Smokers typically see effects within days of using Varenicline Tartrate Tablets, but due to nicotine addiction's complex nature, there is a notable relapse rate, prompting the company to recommend adherence to the treatment regimen [1] Group 3: Competitive Landscape - The potential re-entry of Pfizer's smoking cessation drug into the Chinese market could enhance consumer awareness and market education, benefiting the overall market size due to Pfizer's strong brand influence and marketing capabilities [1]

Group 1: Sales Channels and Performance - The company’s smoking cessation drug, Varenicline Tartrate Tablets, utilizes a dual-brand strategy (PariKe and Family Pharmacist) and multiple sales channels, including over 100,000 chain stores and more than 600 hospitals, with online sales primarily through JD, Alibaba, and Meituan [2] - The largest sales volume for the smoking cessation drug currently comes from offline chain channels [2] - Sales in hospital channels have not met company expectations, as most hospitals only have smoking cessation clinics available for one or two half-days a week [3] Group 2: Market Expansion and Effectiveness - The time required to see results from expanding the drug to new cities or regions depends on the pharmacy's execution; well-managed pharmacies may show improvement in 2 to 3 months, while others may take longer [3] - Smokers using Varenicline Tartrate Tablets generally see effects within a few days, but a significant proportion experience relapse due to various physiological and psychological factors [3] Group 3: Competitive Landscape - If Pfizer re-enters the Chinese market with its smoking cessation drug, the company believes it would positively impact the market by increasing consumer awareness and expanding the overall market size [3]

Group 1: Product Efficacy and Side Effects - Varenicline tartrate tablets are recommended by WHO and various clinical guidelines for smoking cessation, with clinically validated efficacy [2] - The incidence of nausea as a side effect is approximately 20%, typically transient within the first 1-2 weeks of use [2][3] Group 2: Insurance and Promotion - Smoking cessation medications are generally not included in the medical insurance directory as per the 2020 interim measures [3] - The company has established a "Quit Smoking with Me" WeChat public account to promote smoking cessation knowledge [3] Group 3: Sales and Market Expansion - The company has expanded its smoking cessation product to over 100,000 retail stores, with over 60,000 maintained by the company's team [3] - Each sales representative currently covers approximately 400 stores, with plans to increase the team to around 200 members, aiming for coverage of 600 stores each [3] - The highest revenue-generating product is the urological medication, Tamsulosin hydrochloride sustained-release capsules, which has maintained double-digit growth for several years [3]